CJC 1295 without DAC
A modified GHRH analogue (also called modified GRF 1-29) that produces short, physiologic GH pulses.
How it works
Binds the pituitary GHRH receptor to trigger growth-hormone release. Without DAC the half-life is short (~30 min), preserving natural pulsatility especially when paired with a GHRP.
Reported benefits
- Increases endogenous GH and IGF-1 within physiologic ranges
- Improved sleep architecture in some reports
- Supports lean-mass and recovery goals
Dosage & administration
Research range: 100 mcg subcutaneously 1-3x daily, often combined with ipamorelin 100-200 mcg.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Pharmacology of GHRH analogues
Endocrine Reviews · 2010
Modified GRF 1-29 shown to elicit physiologic GH pulses without sustained elevation.
Safety & warnings
- Possible flushing, head-rush, fatigue
- Avoid in active malignancy, pregnancy, or untreated diabetic retinopathy
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
2 mg
CND2
Box of 10 · $123
Single vial · $246
5 mg
CND5
Box of 10 · $285
Single vial · $570
10 mg
CND10
Box of 10 · $555
Single vial · $1,110
Related guides
BPC 157
A pentadecapeptide derived from human gastric juice with broad regenerative effects in pre-clinical models.
TB500 (Thymosin B4 Acetate)
A synthetic fragment of thymosin β-4 that promotes cell migration, angiogenesis, and tissue repair.
BPC + TB Blend
Combined BPC 157 and TB500 blend used in recovery protocols to overlap angiogenic and cytoskeletal effects.